{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T09:00:19Z","timestamp":1791018019874,"version":"4.1.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2008,9,16]],"date-time":"2008-09-16T00:00:00Z","timestamp":1221523200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2008,10,7]]},"DOI":"10.1038\/sj.bjc.6604671","type":"journal-article","created":{"date-parts":[[2008,9,16]],"date-time":"2008-09-16T20:54:13Z","timestamp":1221598453000},"page":"1050-1055","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":92,"title":["Pharmacogenetic prediction of clinical outcome in advanced colorectal cancer patients receiving oxaliplatin\/5-fluorouracil as first-line chemotherapy"],"prefix":"10.1038","volume":"99","author":[{"given":"L","family":"Par\u00e9","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E","family":"Marcuello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Alt\u00e9s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E del","family":"R\u00edo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L","family":"Sedano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Salazar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Cort\u00e9s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Barnadas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Baiget","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2008,9,16]]},"reference":[{"key":"BF6604671_CR1","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1093\/jnci\/82.12.1046","volume":"82","author":"JP Caussanel","year":"1990","unstructured":"Caussanel JP, Levi F, Brienza S, Misset JL, Itzhaki M, Adam R, Milano G, Hecquet B, Mathe G (1990) Phase I trial of 5-day continuous venous infusion of oxaliplatin at circadian rhythm-modulated rate compared with constant rate. J Natl Cancer Inst 82: 1046\u20131050","journal-title":"J Natl Cancer Inst"},{"key":"BF6604671_CR2","first-page":"8097","volume":"63","author":"KJ Cullen","year":"2003","unstructured":"Cullen KJ, Newkirk KA, Schumaker LM, Aldosari N, Rone JD, Haddad BR (2003) Glutathione S-transferase pi amplification is associated with cisplatin resistance in head and neck squamous cell carcinoma cell lines and primary tumors. Cancer Res 63: 8097\u20138102","journal-title":"Cancer Res"},{"key":"BF6604671_CR3","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/S0300-483X(03)00288-9","volume":"193","author":"GL Dianov","year":"2003","unstructured":"Dianov GL (2003) Monitoring base excision repair by in vitro assays. Toxicology 193: 35\u201341","journal-title":"Toxicology"},{"key":"BF6604671_CR4","doi-asserted-by":"publisher","first-page":"2147","DOI":"10.1093\/bioinformatics\/btg276","volume":"19","author":"K Ding","year":"2003","unstructured":"Ding K, Zhou K, He F, Shen Y (2003) LDA\u2013a java-based linkage disequilibrium analyzer. Bioinformatics 19: 2147\u20132148","journal-title":"Bioinformatics"},{"key":"BF6604671_CR5","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1093\/annonc\/mdf034","volume":"13","author":"CH Kohne","year":"2002","unstructured":"Kohne CH, Cunningham D, Di CF, Glimelius B, Blijham G, Aranda E, Scheithauer W, Rougier P, Palmer M, Wils J, Baron B, Pignatti F, Schoffski P, Micheel S, Hecker H (2002) Clinical determinants of survival in patients with 5-fluorouracil-based treatment for metastatic colorectal cancer: results of a multivariate analysis of 3825 patients. Ann Oncol 13: 308\u2013317","journal-title":"Ann Oncol"},{"key":"BF6604671_CR6","doi-asserted-by":"publisher","first-page":"3050","DOI":"10.1158\/1078-0432.CCR-05-2076","volume":"12","author":"T Lecomte","year":"2006","unstructured":"Lecomte T, Landi B, Beaune P, Laurent-Puig P, Loriot MA (2006) Glutathione S-transferase P1 polymorphism (Ile105Val). predicts cumulative neuropathy in patients receiving oxaliplatin-based chemotherapy. Clin Cancer Res 12: 3050\u20133056, doi:10.1158\/1078-0432.CCR-05-2076","journal-title":"Clin Cancer Res"},{"key":"BF6604671_CR7","first-page":"253","volume":"22","author":"HL McLeod","year":"2003","unstructured":"McLeod HL, Sargent DJ, Marsh S, Fuchs C, Ramanathan RK, Williamson S, Findlay B, Thibodeau S, Petersen G, Goldberg R (2003) Pharmacogenetic analysis of systemic toxicity and response after 5-fluorouracil (5FU)\/CPT-11, 5FU\/oxaliplatin (oxal) or CPT-11\/oxal therapy for advanced colorectal cancer (CRC): results froman intergroup trial [Abstract]. Proc Am Soc Clin Oncol 22: 253","journal-title":"Proc Am Soc Clin Oncol"},{"key":"BF6604671_CR8","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1093\/nar\/16.3.1215","volume":"16","author":"SA Miller","year":"1988","unstructured":"Miller SA, Dykes DD, Polesky HF (1988) A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 16: 1215","journal-title":"Nucleic Acids Res"},{"key":"BF6604671_CR9","doi-asserted-by":"publisher","first-page":"2101","DOI":"10.1158\/1078-0432.CCR-05-1363","volume":"12","author":"V Moreno","year":"2006","unstructured":"Moreno V, Gemignani F, Landi S, Gioia-Patricola L, Chabrier A, Blanco I, Gonzalez S, Guino E, Capella G, Canzian F (2006) Polymorphisms in genes of nucleotide and base excision repair: risk and prognosis of colorectal cancer. Clin Cancer Res 12: 2101\u20132108, doi:10.1158\/1078-0432.CCR-05-1363","journal-title":"Clin Cancer Res"},{"key":"BF6604671_CR10","first-page":"8654","volume":"61","author":"DJ Park","year":"2001","unstructured":"Park DJ, Stoehlmacher J, Zhang W, Tsao-Wei DD, Groshen S, Lenz HJ (2001) A Xeroderma pigmentosum group D gene polymorphism predicts clinical outcome to platinum-based chemotherapy in patients with advanced colorectal cancer. Cancer Res 61: 8654\u20138658","journal-title":"Cancer Res"},{"key":"BF6604671_CR11","first-page":"162","volume":"1","author":"DJ Park","year":"2003","unstructured":"Park DJ, Zhang W, Stoehlmacher J, Tsao-Wei D, Groshen S, Gil J, Yun J, Sones E, Mallik N, Lenz HJ (2003) ERCC1 gene polymorphism as a predictor for clinical outcome in advanced colorectal cancer patients treated with platinum-based chemotherapy. Clin Adv Hematol Oncol 1: 162\u2013166","journal-title":"Clin Adv Hematol Oncol"},{"key":"BF6604671_CR12","first-page":"4","volume":"25","author":"E Raymond","year":"1998","unstructured":"Raymond E, Faivre S, Woynarowski JM, Chaney SG (1998) Oxaliplatin: mechanism of action and antineoplastic activity. Semin Oncol 25: 4\u201312","journal-title":"Semin Oncol"},{"key":"BF6604671_CR13","doi-asserted-by":"publisher","first-page":"6100","DOI":"10.1158\/1078-0432.CCR-05-1083","volume":"11","author":"E Reed","year":"2005","unstructured":"Reed E (2005) ERCC1 and clinical resistance to platinum-based therapy. Clin Cancer Res 11: 6100\u20136102, doi:10.1158\/1078-0432.CCR-05-1083","journal-title":"Clin Cancer Res"},{"key":"BF6604671_CR14","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1200\/JCO.2006.08.1844","volume":"25","author":"A Ruzzo","year":"2007","unstructured":"Ruzzo A, Graziano F, Loupakis F, Rulli E, Canestrari E, Santini D, Catalano V, Ficarelli R, Maltese P, Bisonni R, Masi G, Schiavon G, Giordani P, Giustini L, Falcone A, Tonini G, Silva R, Mattioli R, Floriani I, Magnani M (2007) Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy. J Clin Oncol 25: 1247\u20131254, doi:10.1200\/JCO.2006.08.1844","journal-title":"J Clin Oncol"},{"key":"BF6604671_CR15","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1038\/sj.bjc.6603233","volume":"95","author":"M Saunders","year":"2006","unstructured":"Saunders M, Iveson T (2006) Management of advanced colorectal cancer: state of the art. Br J Cancer 95: 131\u2013138, doi:10.1038\/sj.bjc.6603233","journal-title":"Br J Cancer"},{"key":"BF6604671_CR16","doi-asserted-by":"publisher","first-page":"4298","DOI":"10.1200\/JCO.2001.19.23.4298","volume":"19","author":"Y Shirota","year":"2001","unstructured":"Shirota Y, Stoehlmacher J, Brabender J, Xiong YP, Uetake H, Danenberg KD, Groshen S, Tsao-Wei DD, Danenberg PV, Lenz HJ (2001) ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy. J Clin Oncol 19: 4298\u20134304","journal-title":"J Clin Oncol"},{"key":"BF6604671_CR17","first-page":"3075","volume":"21","author":"J Stoehlmacher","year":"2001","unstructured":"Stoehlmacher J, Ghaderi V, Iobal S, Groshen S, Tsao-Wei D, Park D, Lenz HJ (2001) A polymorphism of the XRCC1 gene predicts for response to platinum based treatment in advanced colorectal cancer. Anticancer Res 21: 3075\u20133079","journal-title":"Anticancer Res"},{"key":"BF6604671_CR18","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1038\/sj.bjc.6601975","volume":"91","author":"J Stoehlmacher","year":"2004","unstructured":"Stoehlmacher J, Park DJ, Zhang W, Yang D, Groshen S, Zahedy S, Lenz HJ (2004) A multivariate analysis of genomic polymorphisms: prediction of clinical outcome to 5-FU\/oxaliplatin combination chemotherapy in refractory colorectal cancer. Br J Cancer 91: 344\u2013354, doi:10.1038\/sj.bjc.6601975","journal-title":"Br J Cancer"},{"key":"BF6604671_CR19","doi-asserted-by":"publisher","first-page":"6212","DOI":"10.1158\/1078-0432.CCR-04-2216","volume":"11","author":"J Viguier","year":"2005","unstructured":"Viguier J, Boige V, Miquel C, Pocard M, Giraudeau B, Sabourin JC, Ducreux M, Sarasin A, Praz F (2005) ERCC1 codon 118 polymorphism is a predictive factor for the tumor response to oxaliplatin\/5-fluorouracil combination chemotherapy in patients with advanced colorectal cancer. Clin Cancer Res 11: 6212\u20136217, doi:10.1158\/1078-0432.CCR-04-2216","journal-title":"Clin Cancer Res"},{"key":"BF6604671_CR20","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1093\/carcin\/19.2.275","volume":"19","author":"MA Watson","year":"1998","unstructured":"Watson MA, Stewart RK, Smith GB, Massey TE, Bell DA (1998) Human glutathione S-transferase P1 polymorphisms: relationship to lung tissue enzyme activity and population frequency distribution. Carcinogenesis 19: 275\u2013280","journal-title":"Carcinogenesis"},{"key":"BF6604671_CR21","first-page":"289","volume":"8","author":"M Welfare","year":"1999","unstructured":"Welfare M, Monesola Adeokun A, Bassendine MF, Daly AK (1999) Polymorphisms in GSTP1, GSTM1, and GSTT1 and susceptibility to colorectal cancer. Cancer Epidemiol Biomarkers Prev 8: 289\u2013292","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"BF6604671_CR22","unstructured":"WHO (1979) World Health Organization: Handbook for Reporting Results of Cancer Treatment. Publication no. 48. WHO: Geneva, Switzerland"},{"key":"BF6604671_CR23","first-page":"555","volume":"16","author":"JJ Yu","year":"2000","unstructured":"Yu JJ, Lee KB, Mu C, Li Q, Abernathy TV, Bostick-Bruton F, Reed E (2000) Comparison of two human ovarian carcinoma cell lines (A2780\/CP70 and MCAS) that are equally resistant to platinum, but differ at codon 118 of the ERCC1 gene. Int J Oncol 16: 555\u2013560","journal-title":"Int J Oncol"},{"key":"BF6604671_CR24","first-page":"13","volume":"382","author":"JJ Yu","year":"1997","unstructured":"Yu JJ, Mu C, Lee KB, Okamoto A, Reed EL, Bostick-Bruton F, Mitchell KC, Reed E (1997) A nucleotide polymorphism in ERCC1 in human ovarian cancer cell lines and tumor tissues. Mutat Res 382: 13\u201320","journal-title":"Mutat Res"}],"updated-by":[{"DOI":"10.1038\/sj.bjc.6605004","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2009,4,14]],"date-time":"2009-04-14T00:00:00Z","timestamp":1239667200000}}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/6604671.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/6604671","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/6604671.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T12:35:47Z","timestamp":1684413347000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/6604671"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,9,16]]},"references-count":24,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2008,10,7]]}},"alternative-id":["BF6604671"],"URL":"https:\/\/doi.org\/10.1038\/sj.bjc.6604671","relation":{"erratum":[{"id-type":"doi","id":"10.1038\/sj.bjc.6605004","asserted-by":"object"}]},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,9,16]]},"assertion":[{"value":"3 July 2008","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2008","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 August 2008","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2008","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 November 2011","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}}]}}